# ReT01 ACT

Source: https://onco.cc/drugs/ret01/  
OnCo record `ret01` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ReT01 ACT is an experimental autologous tumour-infiltrating lymphocyte cell therapy from Beijing Xunsheng Biomedical Research, in phase 1 trials for advanced cervical cancer after failure of first-line systemic therapy and advanced solid tumours.

## Summary

ReT01 ACT (ReT01, Re-TIL) is an autologous tumour-infiltrating lymphocyte (TIL) cell therapy from Beijing Xunsheng Biomedical Research. TILs grown from the patient's own tumour tissue by the company's activation and expansion process and infused back; the company says it is given without lymphodepletion and without IL-2 injection. Its furthest stage is phase 1, for advanced cervical cancer after failure of first-line systemic therapy and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 in advanced solid tumours recruiting (NCT06257680); company recruitment page says 临床 Ⅱ 期 for cervical cancer, but no phase 2 registry record was found, so phase 1 is used. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: ReT01; Re-TIL
- Tags: pipeline; ctgov-ingest
- Code: ReT01
- Modality: Autologous tumour-infiltrating lymphocyte (TIL) cell therapy
- Mechanism: TILs grown from the patient's own tumour tissue by the company's activation and expansion process and infused back; the company says it is given without lymphodepletion and without IL-2 injection.

## Sources

- Beijing Xunsheng Biomedical Research: aeonvital.com: http://www.aeonvital.com/page141
- Beijing Xunsheng Biomedical Research: aeonvital.com: http://www.aeonvital.com/page139
- Beijing Xunsheng Biomedical Research: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06257680
- ClinicalTrials.gov: trials of ReT01: https://clinicaltrials.gov/search?intr=ReT01

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Beijing Xunsheng Biomedical Research](https://onco.cc/companies/beijing-xunsheng-biomedical/)
- trials: [A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct06257680/)

---
JSON: https://onco.cc/api/v1/entities/ret01.json